Data Dictionary - Fields

Field	Description	
	Calendar year of clinical care under review. For example, "2011" represents a review in 2012 of clinical	
	care provided between 1/1/2011 and 12/31/2011.	
Year		
	The geographic region in which each clinic is located. Each New York City borough constitutes a region; there are five other	
Region	regions for the rest of the state (Central-West, Long Island, Lower Hudson, Mid-Hudson and Northeast).	
	The name of the clinic providing care. Separate reviews are conducted for each site within a multi-site organization. Program	
Program_name	names are also generated for regional and statewide averages.	
	Classification of the provider organization. Values include "Community Health Center," "Designated	
	AIDS Center" (DAC), "Drug Treatment Center" and "Hospital (non-DAC)."	
Facility_type		
Address	Street address of the clinic providing care.	
City	City of the clinic providing care.	
Zip	Zip Code of the clinic providing care.	
Location	Longitude and latitude of the clinic expressed as paired values within parentheses ("geocode").	
Indicator_name	Name of the clinical performance indicator. See NYSDOH_HIVAmbulatoryCare_IndicatorGuide_2011.pdf.	
Number of patients in the sample for the clinic that were eligible for each particular indicator. For example, number of		
	patients in the sample for the cervical Pap indicator, or number of patients at least 50 years old for the colonoscopy indicators. If	
Eligible_patients	five or fewer, this field and the corresponding Indicator value field are redacted.	
Indicator_value	The percentage of "yes" responses ("score") for each indicator.	
_	The results for each indicator are grouped into the "top 20%," the "second highest 20%," etc.; these are referred to as	
	"quintiles." This field displays these findings for each clinic. ("First" is the highest; "Fifth" is the lowest.) This value is not	
	displayed if (a) there were not at least six patients at a particular clinic or (b) separation by quintiles cannot be achieved due to	
Quintile	limited spread of results (e.g., 80th percentile = 100%).	

04/22/2013 1 of 7

Data Dictionary - Indicators

Primary QI Indicator?	Indicator Name	Denominator	Numerator
*			Patients who were seen at least once during all
	New Patient Retention	period Patients on ART for a minimum of 12 weeks	subsequent four-month review period trimesters
		Patients on ART for a minimum of 12 weeks	Patients who are considered suppressed as derived from the last recorded viral load of the review period;
			i de la companya de
			suppressed defined as the viral load is < 200 cells/mm ³
			(either detectable or undetectable) OR < 400
*	Cumpressed on last viral load		copies/mm³ (and undetectable)
	Suppressed on last viral load	Patients on ART for a minimum of 12 weeks	Patients who are considered suppressed throughout
		rations on Art 101 a minimum of 12 weeks	the review period; suppressed defined as the viral load
			is < 200 cells/mm ³ (either detectable or undetectable)
*	Viral suppression (always)		OR < 400 copies/mm ³ (and undetectable)
	. [Patients who began ARV therapy for the first time during the review	Patients who are considered suppressed as derived
		period	from the last recorded viral load of the review period
		pe.104	after 12 weeks of initiation of therapy; "suppressed"
			defined as the viral load is <200 copies/mm3 (either
	ART naïve patients suppressed on		detectable or undetectable) OR <400 copies/mm3 (and
	last viral load after 12 weeks on		undetectable)
	ART	0	0
		Patients who began ARV therapy for the first time during the review	Patients who are considered suppressed throughout
		period	the review period after 12 weeks of initiation of
	ART naïve patients always		therapy; "suppressed" defined as the viral load is <200
	suppressed after 12 weeks on		copies/mm3 (either detectable or undetectable) OR
	ART		<400 copies/mm3 (and undetectable)
	AIVI	Patients who began ARV therapy for the first time during the review	Patients who are ever considered virologically
		period	suppressed during the review period after 12 weeks of
		PC.104	initiation of therapy; "suppressed" defined as the viral
	ART naïve patients ever		load is <200 copies/mm3 (either detectable or
	suppressed after 12 weeks on		undetectable) OR <400 copies/mm3 (and undetectable)
	ART		and directions

04/22/2013 2 of 7

Data Dictionary - Indicators

Primary QI			
Indicator?	Indicator Name	Denominator	Numerator
		All patients	Patients for whom at least one viral load test was
			performed in each six month semester of the review
*	Viral load every six months		period at least 60 days apart
		All patients	Patients for whom at least one viral load test was
			performed in each four-month trimester of the review
	Viral load every four months		period at least 60 days apart
4	6541	All patients	Patients for whom one or more CD4 count was
т	CD4 during review period		performed during the review period
		All patients	Patients for whom one or more CD4 count was
	CD4 every six months		performed in each six month semester of the review
	CD4 every 31x months	Patients who have an ART start date before the start of the review	period at least 60 days apart Patients for whom ART drugs were prescribed during
		period OR who have one or more CD4 counts recorded during the	the review period
*	ART for CD4 under 500	review period of <500 cells/mm ³	the review period
	ANT TOT CD4 under 500	All patients	Patients for whom adherence is assessed
		zai putients	(quantitatively or qualitatively) during the review
*	Adherence assessment		period
•••••		Patients with one clinical visit in each six month period of the review	Patients for whom a baseline resistance test was
		period who had one or more VL value recorded as >1000	performed during the 90-day period prior to ARV
		copies/mm3 during the review period and prior to ARV initiation,	initiation
	Baseline resistance test (90-day	were ARV-naïve at the start of the review period, and initiated ARV	
*	period prior to ARV initation)	therany the review neriod	
		Patients with one clinical visit in each six month period of the review	Patients for whom a baseline resistance test was
		period who had one or more VL value recorded as >1000	performed at any point prior to ARV initiation (during
	Baseline resistance test (during	copies/mm3 during the review period and prior to ARV initiation,	review period)
*	review period and prior to ARV	were ARV-naïve at the start of the review period, and initiated ARV	
	initation)	therany the review neriod	National with whose substance was ween
		All patients (patients from drug treatment centers excluded)	Patients with whom substance use was
			discussed/assessed during the review period, with
			"never" defined as no history of substance use, "current use" defined as 0-6 months from date of
*	Substance use screening		assessment and "past use" defined as 6 or more

04/22/2013 3 of 7

Data Dictionary - Indicators

Primary QI Indicator?	Indicator Name	Denominator	Numerator
		All patients	Patients for whom all components of a mental health
			screening was performed during the review period
			(components of the mental health screening include:
			screenings for depression, anxiety and PTSD, and
			assessments for cognitive function, domestic violence,
	Mental health screening (all		sleeping habits and appetite)
*	components)		
		All patients	Patients who were screened for PTSD during the review
ļ	PTSD screening		period
		All patients	Patients who were screened for cognitive function
	Cognitive function screening	All c'	during the review period
	A muintu a nagana mina m	All patients	Patients who were screened for anxiety during the
	Anxiety screening	All potionts	review period
	Denression screening	All patients	Patients who were screened for depression during the
 	Depression screening	All patients	review period Patients who received a sleeping habits assessment
	Sleeping habits screening	All patients	during the review period
	Siceping nations serecting	All patients	Patients who received a domestic violence assessment
	Domestic violence screening	, in patients	during the review period
		All patients	Patients who received an appetite assessment during
	Appetite screening		the review period
		All patients	Patients who received a syphilis screening during the
*	Syphilis screening		review period
		All patients	Patients who had one or more urine/cervical/urethral
			tests for Chlamydia during the review period
*	Genital Chlamydia screening		
		All patients	Patients who had one or more urine/cervical/urethral
			tests for gonorrhea during the review period
*	Genital gonorrhea screening		
		All patients	Patients whose Hepatitis C serostatus was known
			(positive or negative) by the end of the review period
ata	Hepatitis C status known		and all patients who had a known (positive or negative)
*	(serostatus and/or RNA)		RNA status

04/22/2013 4 of 7

Data Dictionary - Indicators

Primary QI Indicator?	Indicator Name	Denominator	Numerator
*	Retesting of high-risk patients for Hepatitis C	Patients who had a known negative Hepatitis C antibody status at the beginning of the review period and were at high risk of infection during the review period (active IDU or multiple sexual partners or new abnormal LETs	Patients who were retested for Hepatitis C during the review period
*	Further evaluation of Hepatitis C RNA positive patients	Patients with whose Hepatitis C RNA status was known to be positive during the review period	Patients with whom further treatment or evaluation was discussed during the review period
	Hepatitis C status known (serostatus only)	All patients	Patients whose Hepatitis C antibody status was known (positive or negative) by the end of the review period
	Hepatitis C retesting within 5 years	Patients who are known to be Hepatitis C antibody negative based on their most recent antibody screen (before or during the review period)	Patients whose most recent Hepatitis C antibody screen occurred in the last five years
*	GYN Pap exam	Female patients	Patients who received a cervical Pap test during the review period
*	Latent TB infection screening	Patients who are not being treated for tuberculosis and did not have a known history of TB exposure, tuberculosis or previous positive LTBI screening result	Patients for whom an LTBI screening was performed and the results were read either during the review period or the twelve months preceding the start of the review period.
4		Patients with one or more CD4 counts recorded as <200 cells/mm3 during the review period (excluded if (i) there was only one CD4 < 200; (ii) this ocurred during first six months of review; and (iii) there	Patients who were prescribed prophylactic therapy
*	PCP prophylaxis Influenza vaccination	was a subsequent CD4.>= 200) All patients	Patients who received an influenza vaccination during the review period
*	·	All patients	Patients who received a pneumococcal vaccination either during the review period or the 4 years preceding the start of the review period
*	Tobacco screening	All patients	Patients with whom tobacco use was discussed/assessed during the review period
*	Oral health exam	All patients	Patients who received an oral health exam during the review period
	Mammography during last two years (age 40+)	Female patients who are aged 40 years and older	Patients who received a mammogram either during the review period

04/22/2013 5 of 7

Data Dictionary - Indicators

Primary QI Indicator?	Indicator Name	Denominator	Numerator
			Patients who received a mammogram either during the
	Mammography during last two		review period or the twelve-months preceding the start
	years (age 50+)	Female patients aged 50 or above	of the review period
		All patients	Patients for whom an anorectal exam was performed
*	Anorectal exam		during the review period
		Patients who are MSM, female and had an abnormal cervical and/or	Patients for whom an anal pap test was performed
*	Anal Pap test	vulvar histology, or otherwise have a history of anogenital condyloma	during the review period
		All patients aged 50 or above	Patients who received a colon cancer (colonoscopy)
*	Colonoscopy (age 50 or above)		exam during the past 10 years
		All patients	Patients for whom a laboratory urinalysis was
*	Urinalysis		performed during the review period
		All patients	Patients for whom fasting blood glucose level or plasma
			glucose level obtained from Oral Glucose Tolerance
			Test (OGTT) was measured, and/or HbA1c test was
*	Diabetes screening		performed during the review period
		Patients with an HbA1c test result of ≥ 6.5% OR fasting blood glucose	Patients for whom serum creatinine measurement was
*	Serum creatinine screening	≥126 mg/DL OR Oral Glucose Tolerance Test (OGTT) ≥200	performed during the review period
***************************************		Patients with an HbA1c test result of ≥ 6.5% OR fasting blood glucose	Patients for whom a retinal exam was performed
*	Retinal exam	≥126 mg/DL OR Oral Glucose Tolerance Test (OGTT) ≥200	during the review period
		All patients	Patients for whom one or more blood pressure
		Process of	measurements were performed during the review
*	Hypertension screning		period
		Patients with Stage 1 or Stage 2 HTN based on most recent blood	Patients who were treated as required depending on
		pressure reading during the review period: a) stage 2 systolic blood	stage (with at least 2 medications if stage 2; lifestyle
		pressure >=160 OR diastolic blood pressure >=100; b) stage 1 systolic	modification or medication if stage 1)
	Hypertension treatment (all	blood pressure >=140 OR diastolic blood pressure >=90;	- ·
	hypertensive patients)		

04/22/2013 6 of 7

Data Dictionary - Indicators

Primary QI			
Indicator?	Indicator Name	Denominator	Numerator
		All patients	Patients for whom a lipid screening was performed
			during the review period. At a minimum, lipid screening
			should include determination of cholesterol, high-
			density lipoprotein (HDL) and triglyceride levels
*	Lipid screening		
		All patients	All patients who had a documented history of a health
			literacy screen at this clinic (not necessarily during the
*	Health literacy screening		review period)
		All patients	Patients who received general HIV education during the
*	General patient education		review period
*	Prevention education	All patients	Patients who received prevention education during

04/22/2013 7 of 7